Scientific publications

EUSOMA quality indicators for non-metastatic breast cancer: An update

Dec 26, 2023 | Magazine: European Journal of Cancer

Isabel T Rubio  1 , Lorenza Marotti  2 , Laura Biganzoli  3 , Cynthia Aristei  4 , Alexandra Athanasiou  5 , Christine Campbell  6 , Fatima Cardoso  7 , Maria Joao Cardoso  8 , Charlotte E Coles  9 , Manuela Eicher  10 , Nadia Harbeck  11 , Andreas Karakatsanis  12 , Birgitte V Offersen  13 , Ruud Pijnappel  14 , Antonio Ponti  15 , Peter Regitnig  16 , Donatella Santini  17 , Francesco Sardanelli  18 , Tanja Spanic  19 , Zsuzsanna Varga  20 , Marie Jeanne T F D Vrancken Peeters  21 , Yvonne Wengström  22 , Lynda Wyld  23 , Giuseppe Curigliano  24

Introduction: Quality care in breast cancer is higher if patients are treated in a Breast Center with a dedicated and specialized multidisciplinary team. Quality control is an essential activity to ensure quality care, which has to be based on the monitoring of specific quality indicators. Eusoma has proceeded with the up-dating of the 2017 Quality indicators for non-metastatic breast cancer based on the new diagnostic, locoregional and systemic treatment modalities.

Methods: To proceed with the updating, EUSOMA setup a multidisciplinary working group of BC experts and patients' representatives. It is a comprehensive set of QIs for early breast cancer care, which are classified as mandatory, recommended, or observational. For the first time patient reported outcomes (PROMs) have been included. As used in the 2017 EUSOMA QIs, evidence levels were based on the short version of the US Agency for Healthcare Research and Quality.

Results: This is a set of quality indicators representative for the different steps of the patient pathway in non-metastatic setting, which allow Breast Centres to monitor their performance with referring standards, i.e minimum standard and target.

Conclusions: Monitoring these Quality Indicators, within the Eusoma datacentre will allow to have a state of the art picture at European Breast Centres level and the development of challenging research projects.

CITATION  Eur J Cancer. 2023 Dec 26:198:113500.  doi: 10.1016/j.ejca.2023.113500